MedTrace Logo

Open Label Phase 2 Feasibility Study of BPX-04 Topical Minocycline Gel in Rosacea

NCT03050086 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2019-01-31

No results posted yet for this study

Summary

An open label feasibility study using BPX-04 topical minocycline gel in papulopustular rosacea.

Conditions

  • Moderate to Severe Papulopustular Rosacea

Interventions

DRUG

BPX-04 1% minocycline topical gel

once daily administration of topical minocycline gel to face

DRUG

BPX-04 2% minocycline topical gel

once daily administration of topical minocycline gel to face

DRUG

BPX-04 vehicle topical gel

once daily administration of topical minocycline gel to face

Sponsors & Collaborators

  • BioPharmX, Inc.

    lead INDUSTRY

Principal Investigators

  • AnnaMarie Daniels · BioPharmX, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-29
Primary Completion
2018-06-19
Completion
2018-06-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03050086 on ClinicalTrials.gov